Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer

Cancer Research

Volumn 75, Issue 1, 2015, Pages 22-30

  Galanis, Evanthia ^a   Atherton, Pamela J ^a   Maurer, Matthew J ^a   Knutson, Keith L ^b,c   Dowdy, Sean C ^a   Cliby, William A ^a   Haluska, Paul ^a   Long, Harry J ^a   Oberg, Ann ^a   Aderca, Ileana ^a   Block, Matthew S ^a   Bakkum Gamez, Jamie ^a   Federspiel, Mark J ^a   Russell, Stephen J ^a   Kalli, Kimberly R ^a   Keeney, Gary ^a   Peng, Kah Whye ^a   Hartmann, Lynn C ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Vaccine and Gene Therapy Institute of Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; FOLATE RECEPTOR 1; IODINE 123; MEASLES VIRUS VECTOR; MEMBRANE COFACTOR PROTEIN; NECTIN 4; RECEPTOR; SODIUM IODIDE SYMPORTER; UNCLASSIFIED DRUG; VIRUS VECTOR; COTRANSPORTER; ONCOLYTIC VIRUS;

ADULT; ANTIGEN RECOGNITION; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG TOLERABILITY; EFFECTOR CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOSYNTHESIS; COHORT ANALYSIS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; MEASLES VIRUS; METABOLISM; MIDDLE AGED; MOUSE; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROCEDURES; TRANSGENE; VIROLOGY;

ANIMALS; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEASLES VIRUS; MICE; MIDDLE AGED; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OVARIAN NEOPLASMS; SYMPORTERS; TRANSGENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84920644561     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2533     Document Type: Article

References (46)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Ferrandina G, Ludovisi M, Lorusso D, Pignata S, Breda E, Savarese A, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008;26:890-6.
3. Vergote I, Finkler N, del Campo J, Lohr A, Hunter J, Matei D, et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 2009;45:2324-32.
4. Lamb RA, Kolakofsky D, editors. Paramyxoviridae: the viruses and their replication. 4th ed. Philadelphia, PA: Lippincott-Raven Publishers; 2001.
5. Markman M, Blessing J, Rubin SC, Connor J, Hanjani P, Waggoner S. Phase II trial of weekly paclitaxel (80mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006;101:436-40.
6. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinumbased chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 1994;12:1748-53.
7. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:5165-71.
8. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;25:5180-6.
9. Hartkopf AD, Fehm T, Wallwiener D, Lauer U. Oncolytic virotherapy of gynecologic malignancies. Gynecol Oncol 2011;120:302-10.
10. Raki M, Rein DT, Kanerva A, Hemminki A. Gene transfer approaches for gynecological diseases. Mol Ther 2006;14:154-63.
11. Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562-9.
12. Rocconi RP, Numnum TM, Stoff-Khalili M, Makhija S, Alvarez RD, Curiel DT. Targeted gene therapy for ovarian cancer. Curr Gene Ther 2005;5:643-53.
13. Kim KH, Dmitriev I, O'Malley JP, Wang M, Saddekni S, You Z, et al. A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res 2012;18:3440-51.
14. Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, Aurigemma R, et al. A phase I clinical trial of Ad5/3-Delta24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol 2013;130:518-24.
15. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993;75:295-305.
16. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000;406:893-7.
17. Muhlebach MD, Mateo M, Sinn PL, Prufer S, Uhlig KM, Leonard VH, et al. Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature 2011;480:530-3.
18. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971;2:105-6.
19. Taqi AM, Abdurrahman MB, Yakubu AM, Fleming AF. Regression of Hodgkin's disease after measles. Lancet 1981;1:1112.
20. Cutts FT, Markowitz LE. Successes and failures in measles control. J Infect Dis 1994;170 Suppl 1:S32-41.
21. Bjorge L, Hakulinen J, Wahlstrom T, Matre R, Meri S. Complementregulatory proteins in ovarian malignancies. Int J Cancer 1997;70:14-25.
22. Oglesby TJ, White D, Tedja I, Liszewski K, Wright L, Van den Bogarde J, et al. Protection ofmammalian cells from complement-mediated lysis by transfection of human membrane cofactor protein and decay-accelerating factor. Trans Assoc Am Physicians 1991;104:164-72.
23. Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, et al. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 2010;134:835-45.
24. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-63.
25. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010;70:875-82.
26. Hasegawa K, Pham L, O'Connor MK, Federspiel MJ, Russell SJ, Peng KW. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res 2006;12:1868-75.
27. Dingli D, Peng KW, Harvey ME, Greipp PR, O'Connor MK, Cattaneo R, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004;103:1641-6.
28. Langfield KK, Walker HJ, Gregory LC, Federspiel MJ. Manufacture of measles viruses. Methods Mol Biol 2011;737:345-66.
29. Storer BE. Design and analysis of phase I clinical trials. Biometrics 1989;45:925-37.
30. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
31. Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, et al. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin Cancer Res 2010;16:825-34.
32. Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, et al. An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-speci fic immunity in patients with cancer. Cancer Res 2008;68:4893-901.
33. Knutson KL, Krco CJ, Erskine CL, Goodman K, Kelemen LE, Wettstein PJ, et al. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 2006;24:4254-61.
34. Griffin D, Bellini W, editors. Measles virus. 3rd ed. New York: Lippincott- Raven Publishers;1996.
35. Okada H, Sato TA, Katayama A, Higuchi K, Shichijo K, Tsuchiya T, et al. Comparative analysis of host responses related to immunosuppression between measles patients and vaccine recipients with live attenuated measles vaccines. Arch Virol 2001;146:859-74.
36. ClinicalTrials.gov [homepage on the Internet]. NCT00390299: viral therapy in treating patients with recurrent glioblastoma multiforme. Available from: www.clinicaltrials.gov/ct2/show/NCT00390299.
37. ClinicalTrials.gov [homepage on the Internet]. NCT00450814: vaccine therapy with or without cyclophosphamide in treating patients with recurrent or refractory multiple myeloma. Available from: www.clinicaltrials. gov/ct2/show/NCT00450814.
38. Russell SJ, Federspiel MJ, Peng KW, Tong C, Dingli D, Morice WG, et al. Remission of disseminated cancer after systemic oncolytic virotherapy. Mayo Clin Proc 2014;89:926-33.
39. ClinicalTrials.gov [homepage on the Internet]. NCT0153177: intrapleural measles virus therapy in patients with malignant pleural mesothelioma. Available from: www.clinicaltrials.gov/ct2/show/NCT01503177.
40. Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J. Survival following the documentation of platinumand taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol 2004;93:699-701.
41. Colombo N, Kutarska E, Dimopoulos M, Bae DS, Rzepka-Gorska I, Bidzinski M, et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012;30:3841-7.
42. Gordon AN, Tonda M, Sun S, Rackoff W. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1-8.
43. Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol 2012;23:2605-12.
44. Mader EK, Maeyama Y, Lin Y, Butler GW, Russell HM, Galanis E, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009;15:7246-55.
45. Engeland CE, Grossardt C, Bossow S, Lay-Mees C, Shevchenko I, Umansky V, et al. Measles virus mediated immune checkpoint blockade enhances cancer immunovirotherapy. Mol Ther 2014;22:s11.
46. Hardcastle J, Feng J, Kurokawa C, Domingo-Musibay E, Allen C, Johnson E, et al. Modulation of innate immunity with CTLA4 blockade in measles virotherapy for glioblastoma. Mol Ther 2014;22:s247 (abstr 641).